Market News How it works Learn FAQ
| RCT 0.1111 45.99% | NU 12.415 -18.11% | EWZ 33.695 -20.89% | TGL 0.245 10.61% | BBD 2.875 -29.36% | AZTR 1.75 144.76% | SRTM 0.3361 -21.89% | ITUB 7.655 -20.84% | NVD 3.991 -4.75% | XP 15.635 -48.59% | SHFS 0.0996 -24.77% | SOXL 92.26 10.41% | SPCX 148.545 0.72% | PBR 22.22 -15.06% | CLRO 4.77 46.77% | VALE 11.94 -3.71% | GCDT 0.1424 -19.14% | INTC 91.4822 5.20% | NWGL 0.0865 5.49% | TSLL 10.955 12.24% | CRWV 56.965 5.03% | NVDA 216.08 2.43% | SOXS 47.02 -10.37% | BITO 10.715 -1.06% | NOK 8.7457 7.44% | SGRY 23.2124 47.38% | GPUS 0.1839 8.88% | RWM 14.465 -0.58% | TSLG 5.4768 12.46% | ABEV 2.805 -15.00% | IREN 26.31 5.64% | RBNE 0.1704 -10.32% | JBLU 2.305 -12.19% | INTR 4.505 -37.34% | TQQQ 68.81 3.80% | SPDN 8.485 -0.64% | SBS 4.595 -28.20% | AAL 12.24 1.07% | QID 14.175 -2.58% | TSLA 395.14 6.16% | LUCD 0.5264 28.08% | XTND 2.0901 18.08% | SPRC 1.4801 35.79% | WULF 12.38 9.36% | NFLX 63.145 -4.11% | SID 0.9294 -21.24% | CIFR 7.995 0.69% | SQQQ 38.17 -3.81% | T 21 0.33% | PBR-A 19.54 -16.96%
BCAtreca, Inc. logo

Atreca, Inc. (BCEL)

NASDAQ Global Select · Currency in USD
$0.09 ▼ 0.00 (-1.32%)
As of Jun 14, 3:28 PM ET. Market open.

Summary

Previous Close
$0.09
Open
$0.09
Day's Range
$0.09 – $0.09
52 Week Range
$0.05 – $1.20
Volume
122,115
Avg. Volume
169,764
Market Cap
$3.57M
Beta (5Y Monthly)
1.03
PE Ratio (TTM)
--
EPS (TTM)
-$2.52
Earnings Date
--
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$4.00

Profile: Atreca, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
90
CEO
John A. Orwin
Website
atreca.com

Atreca, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing antibody-based immunotherapies for various solid tumor indications. Its lead investigational therapeutic, ATRC-101, is a monoclonal antibody distinguished by its novel mechanism of action and a unique target, both identified through the company's proprietary discovery platform. In in vitro studies, ATRC-101 has demonstrated reactivity with a significant proportion of human ovarian, non-small cell lung, colorectal, and breast cancer samples sourced from diverse patient populations.

Earnings

DateEst.Actual
Nov 14, 2023-$0.38-$0.39Miss
Aug 10, 2023-$0.56-$0.49Beat
May 10, 2023-$0.56-$0.54Beat
Mar 29, 2023-$0.54-$0.55Miss
Nov 10, 2022-$0.73-$0.60Beat
Aug 8, 2022-$0.70-$0.72Miss

Analyst view

Consensus price target
$4.00 ▲ +4,344.4%
Range $4.00 – $4.00
Rating: Buy
Buy 50% · Hold 50% · Sell 0%

Get free alerts on BCEL and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.